- Home
- HCA vs MDT Comparison
HCA vs MDT Comparison
Compare HCA & MDT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | HCA | MDT |
|---|---|---|
| Founded | 1968 | 1949 |
| Country | United States | Ireland |
| Employees | N/A | N/A |
| Industry | Hospital/Nursing Management | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 119.1B | 131.9B |
| IPO Year | 2009 | 2014 |
Fundamental Metrics
Financial Performance| Metric | HCA | MDT |
|---|---|---|
| Price | $473.26 | $87.05 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 21 | 19 |
| Target Price | ★ $528.00 | $109.82 |
| AVG Volume (30 Days) | 920.1K | ★ 7.1M |
| Earning Date | 04-24-2026 | 02-17-2026 |
| Dividend Yield | 0.65% | ★ 3.24% |
| EPS Growth | 28.77 | ★ 30.80 |
| EPS | ★ 28.33 | 2.76 |
| Revenue | ★ $75,600,000,000.00 | $33,537,000,000.00 |
| Revenue This Year | $5.07 | $8.91 |
| Revenue Next Year | $4.90 | $6.71 |
| P/E Ratio | ★ $16.95 | $31.78 |
| Revenue Growth | ★ 7.08 | 3.62 |
| 52 Week Low | $314.43 | $79.55 |
| 52 Week High | $556.52 | $106.33 |
Technical Indicators
Market Signals| Indicator | HCA | MDT |
|---|---|---|
| Relative Strength Index (RSI) | 27.83 | 32.52 |
| Support Level | $461.74 | $85.60 |
| Resistance Level | $483.20 | $88.77 |
| Average True Range (ATR) | 13.78 | 1.59 |
| MACD | -6.51 | 0.17 |
| Stochastic Oscillator | 4.26 | 23.76 |
Price Performance
Historical ComparisonAbout HCA HCA Healthcare Inc.
HCA Healthcare is a Nashville-based healthcare provider organization operating the largest collection of acute-care hospitals in the United States. As of December 2025, the firm owned and operated 190 hospitals and over 2,500 outpatient facillities across 19 states and a small foothold in the United Kingdom.
About MDT Medtronic plc.
One of the largest medical-device companies, Medtronic develops and manufactures therapeutic medical devices for chronic diseases. Its portfolio includes pacemakers, defibrillators, transcatheter heart valves, stents, insulin pumps, spinal fixation devices, neurovascular products, advanced energy, ablation laser therapy, and surgical tools. The company primarily markets its products to healthcare institutions and physicians in the United States, Western Europe, and Japan. Foreign sales account for roughly 50% of the company's total sales.